Navigation Links
Merriman Curhan Ford Acted as Lead Placement Agent in PolyMedix's $20.7 Million Equity Financing
Date:11/17/2009

SAN FRANCISCO, Nov. 17 /PRNewswire-FirstCall/ -- Merriman Curhan Ford Group, Inc. (Nasdaq: MERR) acted as lead placement agent in PolyMedix Inc.'s (OTC Bulletin Board: PYMX) $20.7 million registered public offering of 20.7 million units. The units, which were priced at $1.00 per unit, consist of one share of PolyMedix common stock and one five year warrant to purchase 0.30 of a share of PolyMedix common stock at $1.25 per share.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO)

The company announced the pricing of the public offering on November 11, 2009 and the closing on November 16, 2009. Details on the transaction can be found at PolyMedix's Web site: www.polymedix.com.

About PolyMedix, Inc.

PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix's compounds are based on biomimetics: non-peptide small molecule drugs that mimic the activity of proteins. The Company's antibiotic compound's small molecule mimetics of human host-defense proteins are believed to have a completely different mechanism of action from all current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. These compounds are being developed as broadspectrum, rapid-acting antibiotics for serious systemic and local infections. The Company is also developing polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Company's anticoagulant antagonist compounds reverse the activity of both heparin and low molecular weight heparins, in keeping with our goal of developing an antagonist drug that is safer and easier to use than current approved therapy. PolyMedix plans to file IND applications during the first quarter of 2008 in anticipation of commencing human clinical trials for both its antibiotic drug and its anticoagulant antagonist. For more information, please visit PolyMedix on its website at www.polymedix.com.

About Merriman Curhan Ford

Merriman Curhan Ford (NASDAQ: MERR) is a financial services firm focused on fast-growing companies and the institutions that invest in them. The company offers high-quality investment banking, equity research, institutional services and corporate & venture services, and specializes in five growth industry sectors: CleanTech; Consumer, Media & Internet; Health Care; Natural Resources and Technology. For more information, please go to www.mcfco.com.

Note to Investors

This press release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of the Company.

SOURCE Merriman Curhan Ford


'/>"/>
SOURCE Merriman Curhan Ford
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
2. Bionovo to Present at Merriman Curhan Fords Investor Summit 2008 on September 15th
3. ProMetic to present at Merriman Curhan Fords Investor Summit 2008 on September 16th
4. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
5. Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th
6. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
7. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
8. XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors
9. Helix BioPharma announces $16.9 million private placement of common shares
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Ardea Biosciences Announces $40 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... February 19, 2017 , ... Expanding Portfolio to Include Lab ... equipment with the goal of expanding the reach of its quality and precision ... water analysis meters were introduced into the market in 2014. , The OHAUS ...
(Date:2/18/2017)... IL (PRWEB) , ... February 17, 2017 , ... ... Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow ... Convention Center in Orlando, Fla. , The combined scientific sessions offer ...
(Date:2/18/2017)... , Feb 17, 2017 Research and Markets ... Business Report" report to their offering. ... The report provides separate comprehensive analytics ... , and Rest of World. Annual estimates and forecasts are ... analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... FREMONT, Calif. , Feb. 17, 2017 /PRNewswire/ ... pleased to announce development of a novel system ... in collaboration with the University of Rochester (NY, ... ). The new system is able to ... cancer biomarker, HER2 (Human epidermal growth factor receptor-2) ...
Breaking Biology Technology:
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent market research, ... a new report, Sensors for Robotics: Technologies, Markets and Forecasts ... ... Revenues ... "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine vision, force ...
(Date:1/26/2017)... 26, 2017  Crossmatch, a leading provider of security ... aimed at combatting fraud, waste and abuse in assistance ... the Action on Disaster Relief conference in ... UN agencies and foreign assistance organizations throughout ... abuse are a largely unacknowledged problem in the foreign ...
Breaking Biology News(10 mins):